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Abstract
Background: In 2009, a pandemic (pdm) influenza A(H1N1) virus infection quickly circulated globally resulting in about
18,000 deaths around the world. In Japan, infected patients accounted for 16% of the total population. The possibility of
human-to-human transmission of highly pathogenic novel influenza viruses is becoming a fear for human health and
society.
Methodology: To address the clinical need for rapid diagnosis, we have developed a new method, the ‘‘RT-SmartAmp
assay’’, to rapidly detect the 2009 pandemic influenza A(H1N1) virus from patient swab samples. The RT-SmartAmp assay
comprises both reverse transcriptase (RT) and isothermal DNA amplification reactions in one step, where RNA extraction
and PCR reaction are not required. We used an exciton-controlled hybridization-sensitive fluorescent primer to specifically
detect the HA segment of the 2009 pdm influenza A(H1N1) virus within 40 minutes without cross-reacting with the
seasonal A(H1N1), A(H3N2), or B-type (Victoria) viruses.
Results and Conclusions: We evaluated the RT-SmartAmp method in clinical research carried out in Japan during a
pandemic period of October 2009 to January 2010. A total of 255 swab samples were collected from outpatients with
influenza-like illness at three hospitals and eleven clinics located in the Tokyo and Chiba areas in Japan. The 2009 pdm
influenza A(H1N1) virus was detected by the RT-SmartAmp assay, and the detection results were subsequently compared
with data of current influenza diagnostic tests (lateral flow immuno-chromatographic tests) and viral genome sequence
analysis. In conclusion, by the RT-SmartAmp assay we could detect the 2009 pdm influenza A(H1N1) virus in patients’ swab
samples even in early stages after the initial onset of influenza symptoms. Thus, the RT-SmartAmp assay is considered to
provide a simple and practical tool to rapidly detect the 2009 pdm influenza A(H1N1) virus.
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Introduction
The 2009 pandemic (pdm) influenza A(H1N1) virus, a new
strain of virus identified in Mexico in April 2009, caused outbreaks
on both local and global scales with severe consequences for
human health and the global economy [1–4]. In Japan, the first
2009 pdm A(H1N1) influenza case was reported on May 9, 2009,
followed by more than 200 cases reported in the Osaka and Kobe
areas by May 21, 2009 [5]. Thereafter, the pandemic infection
spread widely throughout Japan, where the numbers of influenza
cases reported per sentinel provider peaked at 39.63 in November
2009 with over 200 fatal cases owing to infection with the 2009
pdm influenza A(H1N1) viruses. The 2009 pdm influenza
A(H1N1) viruses appear to have a high evolutionary rate [6],
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30236and mutated viruses rapidly circulated around Japan via modern
traffic networks. Phylogenic analyses have revealed that the 2009
pdm influenza A(H1N1) viruses in Japan differed between the very
early phase and the peak phase of the pandemic [6,7].
The 2009 pdm influenza virus is a triple combination
comprising RNA segments from both North American and
Eurasian swine influenza and from avian influenza viruses [8].
Namely, the 2009 pdm influenza A(H1N1) virus possesses PB2
and PA genes of North American avian virus origin, a PB1 gene of
human H3N2 virus origin, HA (H1), NP, and NS genes of classical
swine virus origin, and NA (N1) and M genes of Eurasian avian-
like swine virus origin [9,10]. Unlike most avian and swine A
influenza viruses that can sporadically infect humans via animal to
human transmission but lack the ability to be transmitted from
human to human, the 2009 pdm influenza A(H1N1) virus showed
a strong ability to be transmitted from human to human through
respiratory droplets. In the case of infection with the 2009 pdm
influenza A(H1N1) virus, many groups of patients, including the
immune-compromised and those with underlying chronic condi-
tions such as asthma or chronic obstructive pulmonary disease,
were vulnerable to complications that resulted in mortality
[11,12]. According to WHO statistics, this pdm virus has killed
more than 18,000 people since it emerged in April 2009 [5,11].
By May 2010, the pandemic began to taper off, and the number
of cases declined steeply. On August 10, 2010, WHO announced
the post-pandemic period [5]. There are still concerns, however,
that the 2009 pdm influenza A(H1N1) virus might mutate or re-
assort with existing influenza viruses giving it more virulence when
it returns. In fact, the 1918 Spanish flu pdm virus was relatively
mild in its first wave and acquired more virulence when it returned
in the winter [13]. Furthermore, the wide-spread administration of
oseltamivir might contribute to the emergence of oseltamivir-
resistant 2009 pdm influenza A(H1N1) viruses as dominant
variants. Owing to the heavy use of oseltamivir in Japan, the
oseltamivir-resistance mutation rate (1.2%) can be expected to
greatly increase in the upcoming season [14]. Thus, preparedness
on a global scale against a potentially more virulent and/or drug-
resistant strain is highly recommended.
Rapid influenza diagnostic tests (lateral flow immuno-chromato-
graphic tests) were widely used to detect the influenza viral
nucleoprotein antigen; however, they have a relatively low
sensitivity and yield about 30% false negative results [15]. While
PCR is a sensitive method, it requires laborious steps, such as RNA
extraction and reverse transcriptase reaction steps. Therefore, it is
crucially necessary to develop a simple, rapid, and highly sensitive
method that enables clinical detection of the 2009 pdm influenza
A(H1N1) virus. For this reason, we have developed a one-step
method, named ‘‘RT-SmartAmp assay’’, that detects the HA
segment of the 2009 pdm influenza A(H1N1) virus. The SmartAmp
method was previously developed as an isothermal nucleotide
amplification method [16–18]. The RT-SmartAmp assay devel-
oped in this study combines both reverse transcriptase (RT) and
isothermal DNA amplification reactions in a single step, such that
the required detection time is only about 40 min, and tangled RNA
extraction is not required. This paper reports the technical
development and clinical validation of the RT-SmartAmp assay
for rapid detection of the 2009 pdm influenza A(H1N1) virus.
Results
Preparation of SmartAmp primers to detect the HA
segment of the 2009 pdm influenza A(H1N1) virus
Based on data from the NCBI Influenza Virus Resource
database, we have analyzed the nucleotide sequences of the 2009
pdm influenza A(H1N1) virus to obtain consensus nucleotide
sequences and to calculate the mutation rate at each consensus
nucleotide sequence position in the HA segment of the virus. In
addition, we compared these nucleotide sequences between the
2009 pdm influenza A(H1N1) virus and other seasonal A(H1N1)
viruses to calculate the difference scores, as described in Materials
and Methods. Figure 1 depicts both the mutation rate and the
difference score at every nucleotide position in the HA segment of
the 2009 pdm influenza A(H1N1) virus. By considering the criteria
of (a) low mutation rates and (b) high difference scores, we selected
one target sequence region (nucleotide positions 595–1048) in the
HA segment (Figure 1). The sequence of this target region
contained few mutations, but was specific for the 2009 pdm
influenza A(H1N1) virus.
The SmartAmp-based nucleotide amplification reaction re-
quires five different primers: TP, FP, BP, OP1, and OP2 (see
Materials and Methods). These primer candidates were selected
on the basis of algorithms for free energy, probability of base-
pairing, and product size range. After extensive screening with
synthesized oligo-nucleotides as primer candidates, we have
selected one optimal set of SmartAmp primers as shown in
Table 1. The sequence of nucleotides amplified by the SmartAmp
reaction and primer annealing sites are shown in Figures 2A and
2B, respectively. The genomic sequence located between the
annealing sites of the TP and FP primers is the target region that is
amplified by the SmartAmp reaction. In DNA amplification by
SmartAmp, the very important initial step of copying the target
sequence from the template DNA [16] is called an intermediate
product generation step. The OP1 and OP2 primers were
additionally used to accelerate the DNA strand-displacement
process mediated by N-terminal-deleted Aac DNA polymerase.
After the determination of an optimal primer set, 25% of BP
was replaced by Exciton dye-linked BP, namely, BP-Ex, that
functioned as a ‘‘sequence-specific fluorescent primer’’ [19,20]. In
the BP-Ex primer, one thymidine was covalently linked with two
thiazole orange molecules (Table 1). After hybridization to
complementary sequences, the fluorescence of the BP-Ex primer
provided sequence-specific signals for real-time monitoring of the
DNA amplification reactions. We have examined the sensitivity of
the primer set in the SmartAmp reaction by using various copy
numbers of a plasmid DNA carrying an insert of the target
sequence. The minimal level for detection was found to be 50
copies in the SmartAmp reaction mixture (25 ml) (Figure S1).
Sensitivity and selectivity of the RT-SmartAmp assay
Since our aim was to develop the RT-SmartAmp assay method
for detecting the HA segment of the 2009 pdm influenza A(H1N1)
virus, the assay mixture contained 0.25 units of AMV reverse
transcriptase (RT), as described in Materials and Methods. Figure
S2 illustrates our strategy for the RT-SmartAmp assay reaction,
where the first cDNA stand is synthesized from the viral RNA
negative strand encoding the HA segment and two DNA
intermediates are created in the subsequent SmartAmp reaction.
Furthermore, we have established a simple pretreatment
procedure, whereby we used a pretreatment medium containing
5% SDS to dissolve the viral membrane and to facilitate viral
RNA extraction. SDS was thereafter removed by spin chroma-
tography in a micro-tube column packed with Sephacryl S-400
HR gel-filtration resin. In combination with the simple pre-
treatment procedure, we examined the sensitivity and selectivity of
the RT-SmartAmp assay to the 2009 pdm influenza A(H1N1)
virus. For this purpose, we used isolated and cultured influenza
viruses, i.e., 2009 pdm A(H1N1), seasonal A(H1N1), seasonal
A(H3/N2), seasonal B (Victoria). Each of them had a viral titer of
2009 Pdm A(H1N1) Virus Detection by RT-SmartAmp
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7 pfu/ml. Ten microliters from each viral sample was mixed
with 90 ml of pretreatment medium (5% SDS). Subsequently,
15 ml of the suspension was subjected to spin column (Sephacryl S-
400 HR) chromatography. Five microliters of the eluted solution
was then applied to the reaction mixture of the RT-SmartAmp
assay. Figure 3 demonstrates the reaction time courses, where the
fluorescence of BP-Ex was continuously monitored. This RT-
SmartAmp assay was specific to the 2009 pdm influenza A(H1N1)
virus and showed no cross activity with seasonal A(H1N1),
seasonal A(H3/N2), or seasonal B (Victoria). Even after a 10
5-fold
dilution, the 2009 pdm A(H1N1) virus could still be detected by
the RT-SmartAmp assay with the same procedure (Figure 3).
We further tested the cross reactivity of the RT-SmartAmp
assay with other infectious viruses and bacteria, as listed in Table
S1, and confirmed that the RT-SmartAmp reaction was specific to
the 2009 pdm influenza A(H1N1) virus. In this experiment,
however, lysis of Escherichia coli, Klebsiella pneumoniae, and Serratia
marcescens was not completely achieved by the pre-treatment (5%
SDS). Therefore, these bacteria could not be subjected to the RT-
SmartAmp assay.
Clinical study to validate the RT-SmartAmp assay
In the present study, the RT-SmartAmp assay was clinically
validated at three hospitals, i.e., Chiba Prefectural Togane
Hospital, Isumi Medical Center in Chiba, and the National
Center for Global Health and Medicine in Tokyo [6]. About six
months after the first case of infection with the 2009 pdm influenza
virus was reported in Japan in May 2009, the influenza cases
Figure 1. Preparation of SmartAmp primers to detect the HA segment of the 2009 pdm influenza A(H1N1) virus. A. Mutation rate and
difference score in the consensus sequence of the HA segment. Nucleotide sequences of the HA segment of 2009 pdm influenza A(H1N1) viruses
were obtained from the NCBI Influenza Virus Resource database and aligned by using the MUSCLE program to gain the consensus sequence of the
HA segment. The mutation rate at each base position was calculated as described in Materials and Methods. The difference between 2009 pdm and
seasonal A(H1N1) viruses was calculated at each position in the nucleotide sequence of the HA segments to gain the difference score. B: Comparison
of data acquired in 2009 and 2011 as to the mutation rates in the HA segment of the 2009 pdm influenza A(H1N1) viruses.
doi:10.1371/journal.pone.0030236.g001
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that time, the 2009 pdm influenza A(H1N1) viruses had become
the dominant strains [6]. From October 13, 2009, to January 6,
2010, during the peak phase of the pandemic in Japan, we
collected a total of 255 samples from outpatients with influenza-
like symptoms at these three hospitals and eleven clinics associated
with Chiba Prefectural Togane Hospital.
Figure S3 depicts our scheme for the processing of nasopha-
ryngeal swabs from patients and the detection of the 2009 pdm
influenza A(H1N1) virus. Two swab samples were collected from
each patient. One of them was used for the rapid influenza
diagnostic tests, and the other sample was subjected to the RT-
SmartAmp assay of the 2009 pdm influenza A(H1N1) virus. Both
samples were then transferred to RIKEN Yokohama Institute for
sequence analysis of the HA segment.
Before carrying out the 2009 pdm influenza A(H1N1) virus
detection in clinical samples by the RT-SmartAmp assay, we
defined the following criteria for our decision of positive or
negative results. (1) Each assay must meet the two requirements of
no amplification with the negative control and amplification with
the positive control. (2) When the fluorescence intensity is higher
than or equal to 3000 arbitrary units (a.u.) in an Mx3000P real-
time PCR machine at 40 min of the RT-SmartAmp assay, the
sample is regarded as positive for infection. (3) When the
fluorescence intensity is lower than 3000 a.u. at 40 min of the
RT-SmartAmp assay, the sample is regarded as negative for
infection.
Among the 255 collected samples, 140 samples (54.9%) were
detected by the RT-SmartAmp assay as positive in terms of
infection with the 2009 pdm influenza A(H1N1) viruses. In
contrast, by the rapid influenza diagnostic tests, 110 samples
(43.1%) were detected as positive for influenza A infection. Table 2
summarizes the assay results obtained with all of the nasopharyn-
geal swabs from patients in this clinical study. There were 6
samples collected for this study that were scored as negative by the
RT-SmartAmp assay, whereas the commercial rapid testing kit
gave positive results for influenza A infection. To investigate this
discrepancy, we performed quantitative RT-PCR (qRT-PCR) and
sequence analysis for those 6 samples and found that each of them
contained the 2009 pdm influenza A(H1N1) virus at under
detectable levels, whereas sufficient levels of the 2009 pdm
influenza A(H1N1) virus were detected in the samples collected
for the rapid testing. It is likely that such differences in the virus
levels occurred in the process of sampling, because we collected
two separate nasopharyngeal swabs from each patient.
Clinical significance of the RT-SmartAmp method
A total of 132 patients were diagnosed as positive for infection
with the 2009 pdm influenza A(H1N1) virus by the RT-
SmartAmp assay. It should be kept in mind that, in some cases,
Figure 2. The sequence of nucleotides amplified by the SmartAmp reaction and primer annealing sites. A: cDNA encoding the partial
sequence of the HA segment of the 2009 pdm influenza virus and primer annealing sites. B: Schematic illustration of annealing sites of the TP, FP,
OP1, OP2, and BP primers. The size of each annealing site is numerically indicated as the number of base units (b).
doi:10.1371/journal.pone.0030236.g002
Table 1. SmartAmp primers designed for detection of the
2009 pdm influenza A(H1N1) virus.
Primer 59-DNA sequence-39
TP TTCCATTGCGAATGCACATTCGAAGCAAC
FP GCATTCGCGAAATGATAATACCAGATCC
BP ACCACTAGATTTCCAG
BP-Ex ACCACZAGATTTCCAG
OP1 ACACTAGTAGAGCCGGGAGA
OP2 CTGGTGTTTATAGCACCCTT
TP: The turn back region is underlined.
FP: The folding region is underlined.
BP-Ex: The Exciton dye is covalently bound with thymidine that is marked with a
bold ‘‘Z’’.
doi:10.1371/journal.pone.0030236.t001
2009 Pdm A(H1N1) Virus Detection by RT-SmartAmp
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points. In particular when the patients had very serious conditions
or oseltamivir-resistance, multiple samples, i.e., nasopharyngeal
swabs and tracheal fluid samples, were collected. Therefore, the
number (140) of samples was greater than the number (132) of
patients. For the 2009 pdm influenza A(H1N1)-positive patients
diagnosed by the RT-SmartAmp assay, we analyzed clinical
information with respect to the time from fever onset until the
sampling of nasopharyngeal swabs and summarized these data in
Table 3. It is noteworthy that, in 72.8% of the infection-positive
Figure 3. RT-SmartAmp detection of the 2009 pdm influenza A(H1N1) virus with different dilutions as well as the cross activity with
seasonal A(H1N1), seasonal A(H3N2), and B(Victoria) viruses. Isolated and cultured influenza viruses, i.e., 2009 pdm A(H1N1), seasonal
A(H1N1), seasonal A(H3/N2), and seasonal B/Victoria, were prepared at a viral titer of 10
7 pfu/ml. Each viral sample (10 ml), except for the 2009 pdm
influenza A(H1N1) virus, was mixed with 90 ml of the pretreatment medium (5% SDS) to dissolve the viral membrane and to facilitate viral RNA
extraction. A sample (15 ml) of the resulting medium was subjected to spin column chromatography, and the eluted solution (5 ml) was applied to the
RT-SmartAmp reaction mixture. In the case of the 2009 pdm influenza A(H1N1) virus, the viral sample was diluted by 10
3-, 10
4-, or 10
5-fold as
indicated in the figure, and then processed in the same manner as described above. The RT-SmartAmp assay was performed as described in Materials
and Methods.
doi:10.1371/journal.pone.0030236.g003
Table 2. Comparison of results detected by the rapid diagnosis kits and the RT-SmartAmp assay.
Rapid diagnosis kit RT-SmartAmp assay Number of paired samples % Remarks
Influenza A 2009 pdm A(H1N1) 104 40.8 2009 pdm A(H1N1) confirmed by sequence analysis
Influenza A negative 6 2.4 Viruses under detectable level in RT-SmartAmp samples
negative 2009 pdm A(H1N1) 36 14.1 2009 pdm A(H1N1) confirmed by sequence analysis
negative negative 109 42.7 Viruses under detectable level in both samples
As depicted in Figure S3, two swab samples were collected as one pair from each patient. Swab samples were separately used for the rapid influenza diagnostic tests
and RT-SmartAmp assay. All the samples were transferred to RIKEN Yokohama Institute for sequence analysis and RT-Q-PCR detection.
doi:10.1371/journal.pone.0030236.t002
2009 Pdm A(H1N1) Virus Detection by RT-SmartAmp
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influenza A(H1N1) virus within 24 hours after the onset of fever.
Moreover, in about 20% of the cases, the virus was positively
detected by the RT-SmartAmp assay even less than 6 hours after
the onset of fever (Table 3). These results suggest that the RT-
SmartAmp assay is sensitive and clinically useful for detection of
the 2009 pdm influenza A(H1N1) virus in early stages after the
initial onset of flu symptoms.
Fatal case
In the present clinical study, we encountered one fatal case,
wherein a 72-year-old female had preexisting autoimmune
hepatitis with liver cirrhosis. She received daily treatment with
5 mg of prednisolone and 50 mg of azathioprine. Flu-like
symptoms had developed 11 hours before she was transferred by
ambulance to the National Center for Global Health and
Medicine (NCGM) in Tokyo. Upon admission, the patient was
conscious and able to respond to the doctor’s queries. At that time,
the result of the rapid influenza diagnostic test was negative,
whereas the RT-SmartAmp assay gave a positive result from her
nasopharyngeal swab sample (Figure 4A). Therefore, the treat-
ment with oseltamivir was started immediately. Nine hours later,
however, her respiratory condition deteriorated, and she experi-
enced a sudden drop in blood pressure. It was considered a
diagnosis of severe influenza virus pneumonia complicated by
septic shock. The patient was admitted to the intensive care unit
(ICU) and promptly treated with broad-spectrum antibiotics, fluid
resuscitation, norepinephrine, corticosteroids, and double dose
oseltamivir. Figure 4B depicts the chest radiography of the patient,
demonstrating a drastic progression of severe viral pneumonia,
which is characterized by pathological lesions of diffuse alveolar
damage (DAD). Both nasopharyngeal swab and tracheal fluid
samples were taken from the patient and tested with a rapid
influenza diagnostic kit and the RT-SmartAmp assay. The rapid
influenza diagnostic kit again gave negative results with both swab
and tracheal fluid samples. However, the RT-SmartAmp assay
clearly detected the 2009 pdm virus in both samples (Figure 4A). It
appeared that the 2009 pdm influenza A(H1N1) virus level was
gradually decreasing over time, as shown in Figure 4A. In spite of
intensive treatments, however, the patient expired 52 hours after
the onset of fever.
Our sequence analyses revealed that the amino acid residue 185
in the HA protein of the 2009 pdm influenza A(H1N1) virus was
asparagine (N), instead of aspartic acid (D) (Figure 4C), in both
swab and tracheal fluid samples collected from the patient. HA-
Asn185 is located in the Ca antigenic site [6,21], being found in
the HA protein of the reported sequences of the 1918 influenza
viruses [22–23]. There was no mutation associated with
oseltamivir-resistance in the NA segment in this patient (data not
shown).
Oseltamivir-resistance case
We encountered three oseltamivir-resistance cases in our clinical
research. Here, we report a case of severe pneumonia and
encephalopathy associated with oseltamivir-resistant 2009 pdm
influenza A(H1N1) virus. A 6-year-old girl who had been
vaccinated against 2009–10 seasonal influenza was transferred to
NCGM in Tokyo with an 8-hour history of fever (39.9uC) and
chills. Soon after admission, she rapidly became comatose with
febrile convulsions. Nasopharyngeal swab samples were collected
from the patient, and the rapid influenza diagnostic test showed
infection positive with influenza A. A brain CT scan revealed
diffuse and severe edema of the whole brain (Figure 5A).
Moreover, chest radiography of the patient demonstrated slight
infiltrates in both middle and lower lung fields and mild atelectasis
of the right upper lung lobe (Figure 5B). Therefore, the patient was
immediately treated with broad-spectrum antibiotics, high-dose
corticosteroids, and oseltamivir (4 mg/kg/day) in the ICU.
Nevertheless, 6 hours later, she fell into critical respiratory failure
with a ratio of the partial pressure of arterial oxygen (PaO2) to the
fraction of inspired oxygen (FIO2) of 123, and required
mechanical ventilation. Despite the treatments, she produced
more respiratory secretions, which were thick and sticky, and
atelectasis of her lung progressed gradually. The PaO2/FIO2 ratio
of the patient declined to 87 on hospital day 5, and bronchial toilet
with bronchoscopy was required. Both nasopharyngeal swabs and
tracheal fluid samples were tested with the rapid influenza
diagnostic kit and the RT-SmartAmp assay, and the results were
all positive (data not shown).
On hospital day 9, her respiratory condition gradually improved
to a PaO2/FIO2 ratio of 207 with the treatments including
repeated bronchoscopy for the purpose of bronchial toilet and
respiratory physical therapy with discontinuance of skeletal muscle
relaxant. Both nasopharyngeal swabs and tracheal fluid samples
were collected and subjected to the rapid influenza diagnostic test
and the RT-SmartAmp assay. The rapid influenza diagnostic kit
gave negative results, whereas the RT-SmartAmp assay still
detected the 2009 pdm influenza A(H1N1) virus in the tracheal
fluid sample (Figure 5C). Therefore, the patient was treated with
oseltamivir for 14 days. The patient was successfully weaned from
mechanical ventilation on hospital day 13. A repeat brain CT scan
showed alleviated edema in her whole brain (Figure 5A). While
brain edema had to be carefully followed, the patient’s condition
gradually improved and her respiration was well stabilized.
Finally, it took a total of 55 days until the patient recovered
sufficiently to be discharged from the hospital.
Sequence analyses with both nasopharyngeal swabs and
tracheal fluid samples from this patient revealed that the amino
acid residue 275 in the NA protein of the 2009 pdm influenza
A(H1N1) virus was tyrosine (Y), instead of histidine (H) (Figure 5D),
providing evidence that this patient was infected with oseltamivir-
resistant viruses. Furthermore, this clinical case has demonstrated
that the RT-SmartAmp assay is sensitive for detecting the 2009
pdm influenza A(H1N1) virus not only in nasopharyngeal swabs
but also in tracheal fluid samples.
Discussion
Clinical validation of SmartAmp-based detection of the
2009 pdm influenza A(H1N1) virus
Influenza A viruses belong to the family Orthomyxoviridae,
containing a genome composed of eight segments (i.e., PB1, PB2,
Table 3. Time after the onset of fever and the number of
patients who were diagnosed by the RT-SmartAmp assay as
positive for infection with the 2009 pdm influenza A(H1N1)
virus.
Time after onset of fever (hours) Number of patients %
0,Time#62 6 1 9 . 7
6,Time#12 15 11.4
12,Time#18 33 25.0
18,Time#24 22 16.7
24,Time 36 27.2
doi:10.1371/journal.pone.0030236.t003
2009 Pdm A(H1N1) Virus Detection by RT-SmartAmp
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RNA [10]. The HA segment RNA encodes haemagglutinin
protein, which is critical for viral binding to cellular receptors and
fusion of the viral and endosomal membranes. We have selected
the HA segment as a target for the RT-SmartAmp assay, since the
segment gene represents the subtype-specific characteristics of
influenza A viruses. The HA gene of the 2009 pdm influenza
A(H1N1) viruses was reportedly derived from ‘‘classical swine
H1N1’’ virus, which likely shares a common ancestor with the
human H1N1 virus that caused the influenza pandemic in 1918,
and whose descendant viruses continued to circulate in the human
population with highly altered antigenicity of HA [9,24,25].
Studies on the worldwide evolution of the 2009 pdm influenza
A(H1N1) viruses have shown that the 2009 pdm influenza
A(H1N1) viruses appear to have a high mutation rate [26,27].
In our recent study [6] as well as that of Shiino et al. [7],
phylogenetic analyses carried out on Japanese isolates corrobo-
rated the circulation of four clusters, whereas most of the Japanese
isolates were further divided into a total of 24 micro-clades [6].
While we selected the target region (Figure 1A) by considering
the criteria of (a) low mutation rates and (b) high difference scores,
we have investigated whether mutations occurred in the primer-
annealing regions in the HA segment and whether such mutations
could affect the RT-SmartAmp assay. As demonstrated in Figure
S4, sequence analysis of the HA segment revealed that several
mutations occurred in the primer-annealing regions in some swab
samples. For the SmartAmp reaction, TP is the critically
important driver of the amplification process [28]. In the present
clinical study, two mutations were detected, one each in the TP-
annealing and TP-turn back sites. In 14 samples, mutations were
found in the OP1-annealing region, whereas one mutation was
found in the OP2-annealing region in one sample (Figure S4).
Nevertheless, the RT-SmartAmp assay was not greatly affected by
those mutations in the HA segment.
Figure 4. Detection of the 2009 pdm influenza A(H1N1) virus by RT-SmartAmp assay in the fatal case. A: Nasopharyngeal swab samples
were collected at 11, 28, and 52 hours after the onset of fever from the patient who was transferred by ambulance to the National Center for Global
Health and Medicine. The 2009 pdm influenza A(H1N1) virus was immediately detected by the RT-SmartAmp assay as described in Materials and
Methods. B: Chest radiography of the patient was taken at 11 and 28 hours after the onset of fever. C: Partial sequence of the HA segment of the
2009 pdm influenza A(H1N1) virus was analyzed after extraction of viral genome RNA from the swab samples. An arrow indicates the mutation that
caused an amino acid substitution at 185 from aspartate to asparagine (N) in the HA protein.
doi:10.1371/journal.pone.0030236.g004
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assay was estimated to be 50 copies in the reaction mixture (25 ml).
This value was comparable to that of qRT-PCR (the Real Time
ready Influenza A(H1N1) Detection Kit from Roche Diagnosis
GmbH). In this study, we could not directly compare the result of
the RT-SmartAmp assay with that of the Human Influenza Virus
Real-Time RT-PCR Detection and Characterization Panel (rRT-
PCR Flu Panel) of the Centers for Disease Control and Prevention
(CDC), since the rRT-PCR Flu Panel was not timely available
when we started our clinical research. Nevertheless, as demon-
strated in Table 3, in 72.8% of all the infection-positive cases, the
RT-SmartAmp assay could detect the 2009 pdm influenza
A(H1N1) virus within 24 hours after the onset of fever. Thus,
the RT-SmartAmp assay is considered to provide a simple and
practical tool to rapidly detect the 2009 pdm influenza A(H1N1)
virus.
The RT-SmartAmp assay as a point-of-care technology
Methods widely used for the definitive diagnosis and classifica-
tion of influenza virus infections are mainly PCR-based. PCR-
based diagnosis, however, is still relatively complex and expensive,
since PCR requires thermocycling to mediate DNA melting,
primer annealing, and polymerase-aided extension of DNA. More
importantly, PCR-based techniques require Taq DNA polymerase,
which is easily inhibited by impurities, and isolation of viral RNA
is a prerequisite. Conversely, isothermal nucleic acid amplification
technologies use a single reaction temperature, which translates
into less complex and less expensive instrumentation. Indeed, the
isothermal amplification technologies are rapidly growing to cover
various applications, such as pathogen detection and SNP
genotyping [29–32]. The SmartAmp method has been developed
based on the concept that DNA amplification itself is the signal for
the presence of a specific target sequence. Differing from the
widely-used PCR, the SmartAmp reaction is an isothermal DNA
amplification [16–18]. This is a great advantage for our rapid
detection of influenza A viruses, since we can carry out both RT
and isothermal DNA amplification reactions in one reaction tube.
In the SmartAmp method, patient samples are processed by using
the enzyme Aac polymerase. This enzyme is highly resistant to
cellular contaminants.
In addition, we have most recently developed exciton-controlled
hybridization-sensitive fluorescent primers [19,20], named ‘‘Exci-
ton Primers’’, which significantly enhance the signal/noise ratio.
Exciton Primers function as sequence-specific dyes. After hybrid-
ization to complementary sequences, the Exciton Primer provides
a sequence-specific fluorescent signal for real-time monitoring of
amplification reactions [22]. Exciton Primers show high signal
strength with low background leading to a superior specificity and
sensitivity compared to the commonly used SYBRH Green I [22].
Owing to their high signal/noise ratio, Exciton Primers enabled
Figure 5. Detection of the 2009 pdm influenza A(H1N1) virus by the RT-SmartAmp assay in the oseltamivir-resistance case. A:
Images of the head CT scanning taken on hospital day 1 (left) and day 13 (right). B: Chest radiography of the patient taken on hospital day 1 (left) and
day 5 (right). C: The RT-SmartAmp assay with tracheal fluid (#) and nasopharyngeal swab (N) samples collected on hospital day 9. This figure depicts
the time courses of the RT-SmartAmp assay reactions with those samples as well as with positive (m) and negative (n) controls. D: Partial sequence
of the NA segment of the 2009 pdm influenza A(H1N1) virus was analyzed after extraction of viral genome RNA from the swab samples. An arrow
indicates the mutation that caused an amino acid substitution at 275 from histidine (N) to tyrosine (Y) in the NA protein.
doi:10.1371/journal.pone.0030236.g005
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viruses by the RT-SmartAmp assay (data not shown).
Comparison with other isothermal amplification
methods
Recently, a reverse transcription-loop-mediated isothermal
amplification (RT-LAMP) assay has been developed to detect
the 2009 pdm influenza A(H1N1) virus [33–35]. In particular, a
pocket-warmer RT-LAMP [35] may have great potential utility
as an on-site diagnosis tool. LAMP is mainly used for pathogen
detection with rapid and accurate detection [32], whereas
SmartAmp is a particularly useful method for SNP and mutation
detection [16,18]. It is well known that the His-to-Tyr
substitution at amino acid residue 275 confers the 2009 pdm
influenza A(H1N1) virus oseltamivir-resistance, and this mutation
was detected in patients infected with 2009 pdm influenza
A(H1N1) viruses in our clinical study [6]. It has been reported
that the oseltamivir-resistant 2009 pdm influenza A(H1N1)
viruses were as pathogenic and transmittable as their drug-
sensitive counterparts [14]. Since oseltamivir has been heavily
used in pharmaceutical treatments in Japan, the oseltamivir-
resistance rate is expected to greatly increase in the second pdm
virus wave. Therefore, the next challenge for the RT-SmartAmp
assay is to develop a kit for rapid detection of the mutation
causing oseltamivir-resistance.
Furthermore, sample preparation is a bottleneck for nucleic acid
amplification methods, including SmartAmp and LAMP as well as
PCR-based clinical diagnostic applications. In the present study,
we used the pretreatment medium containing 5% SDS to dissolve
the viral membrane and to facilitate viral RNA extraction.
Therefore, the SDS had to be removed from the sample by spin
column chromatography. This step should be improved in future
technology development. Sample preparation starting from
clinical specimens, such as nasopharyngeal swabs, needs to be
coupled with amplification and detection to achieve the final goal
of point-of-care technologies.
Concluding remarks
In conclusion, the present clinical study has verified the
practical usefulness and high sensitivity of the RT-SmartAmp
assay for detection of the 2009 pdm influenza A(H1N1) virus.
Whilst the pandemic tapered off in 2011, outbreak and rapid
spread of influenza virus infection is one of serious concerns in the
North-East area of Japan. On March 11, 2011, extremely strong
earthquakes and huge ‘‘Tsunami’’ waves attacked counties and
provinces in that area. Approximately 20,000 people were killed
by the natural disaster. Over 100,000 people had to evacuate, and
most of the refugees are presently staying in temporary residences
urgently constructed in local areas. It is critically important for
those refugees to prevent the outbreak of any kind of infections
diseases including influenza.
The possibility of human-to-human transmission of highly
pathogenic avian influenza A(H5N1) viruses is becoming a fear for
human health and society. Since the first human cases appeared in
1997 in Hong Kong, A(H5N1) viruses have been circulating
among avian species and have spread throughout Asia, Europe,
and Africa, with sporadic transmission to humans [36–38] and
reports of nearly 60% mortality [39]. In this context, simple, cost-
effective, and highly sensitive methods should be developed to
detect influenza A(H5N1) viruses. As demonstrated in this study,
the RT-SmartAmp assay would provide a practical tool to support
rapid diagnosis of influenza virus infection and to prevent
pandemic as well as endemic infection among humans.
Materials and Methods
Collection of influenza viral sequences and data analyses
Nucleotide sequences of the HA segment of 2009 pdm influenza
A(H1N1) viruses were obtained from the NCBI Influenza Virus
Resource database (http://www.ncbi.nlm.nih.gov/genomes/
FLU/SwineFlu.html), and the HA sequences (longer than 1600
bases) were aligned by using the MUSCLE program [36]. The
base composition, i.e.,P i(x) (i=A, T, G, or C), was obtained for
each position (x) in the aligned nucleotide sequence of the HA
segment. The consensus sequences were determined as the bases
of the highest base compositions. The mutation rate at each
consensus sequence position was calculated as the summation of
the non-consensus base compositions. Example: mutation rate
P(x)=PA(x)+PT(x)+PG(x), in the case where the consensus
nucleotide is C at position (x).
The nucleotide sequences of the HA segment of seasonal H1N1
viruses reported since the year of 2004 were also obtained from the
NCBI Influenza Virus Resource database and aligned in the same
way as described above. The consensus sequences of the HA
segment of 2009 pdm and seasonal H1N1 viruses were then
aligned according to [40]. The difference between 2009 pandemic
and previous seasonal H1N1 viruses was calculated at each
position (x) in the nucleotide sequence of the HA segments
according to the following the formula:
Difference score(x)~1{
X
i~A,T,G,C
Pi,2009pdm(x)|Pi,seasonal(x)
  
where x means the position in the HA nucleotide sequence, i=A,
T, G, or C.
Design of SmartAmp primer candidates
Based on the above-mentioned data analysis, one nucleotide
region in the HA segment of the 2009 pdm influenza A(H1N1)
virus was selected as a target candidate for SmartAmp primers.
The criteria for selecting a target candidate were: (a) total mutation
rates are low, and (b) total difference scores are high within a given
partial nucleotide sequence. Candidates of SmartAmp primers
were designed, i.e., turnback primer (TP), boost primer (BP),
forward primer (FP), and two outer primers (OP1 and OP2). The
nucleotide sequence between the annealing sites of the TP and FP
primers gives the actual target region to be amplified by the
SmartAmp reaction. Primer candidates were selected based on
algorithms [41] considering the free energy, probability of base-
pairing, and product size range.
Screening and optimization of SmartAmp primers
A variety of oligo-nucleotides were synthesized as primer
candidates and screened in the standard SmartAmp reaction.
Each reaction mixture (total volume of 25 ml) for the screening
contained 1.82 mM each of FP and TP, 0.23 mM each of OP1 and
OP2, 0.91 mM BP, 1.4 mM dNTPs, 20 mM Tris-HCl (pH 8.0),
10 mM KCl, 10 mM (NH4)2SO4, 8 mM MgSO4, 0.1% TweenH
20, 1/100,000 diluted original SYBRH Green I (TaKaRa BIO
INC., Kyoto, Japan), 6 units of Aac DNA polymerase (K.K.DNA-
FORM, Yokohama, Japan), and about 10,000 copies of plasmid
DNA with an insert of the target sequence. All experiments of the
SmartAmp reaction were performed in an Mx3000P real-time
PCR machine (Agilent Technologies, La Jolla, CA, USA) by
maintaining the reaction temperature at 60uC and monitoring of
changes in the fluorescence intensity with an FAM (band pass
width of 492 nm–516 nm) filter.
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Exciton-controlled hybridization-sensitive fluorescent Primers
tagged with thiazole orange, named ‘‘Exciton Primers’’, were
synthesized on solid support using standard phosphoramidite
chemistry and purified by using HPLC, as described previously
[19,20]. After the primer set was determined, 25% of BP was
replaced by BP Exciton Primer (BP-Ex).
RNA synthesis by in-vitro transcription
RNA encoding the target sequence for the SmartAmp reaction
was in-vitro synthesized by using the CUGA7H in vitro Transcription
Kit (Nippongene, Japan) according to the manufacturer’s protocol.
Prior to the in-vitro transcription reaction, a template DNA
fragment including a T7 promoter sequence was first created by
PCR with SYBRH Premix Ex Taq
TM (Takara Bio Inc., Japan),
and the plasmid DNA carrying the target sequence. PCR primers
(59-CTAATACGACTCACTATAGGGCCATCTACTAGTGC-
TGACCA-39 and 59-CCCTTCA ATGAAACCGGCAA-39) were
designed to amplify the target sequence (positions 595–1048 in the
HA segment). The PCR reaction was started with a DNA
denaturation step (95uC for 5 min) and followed by a total of 35
cycles of thermocycling reactions (95uC for 30 sec, 60uC for
30 sec, 72uC for 30 sec) and a final extension reaction at 72uC for
3 min. The resulting PCR product was purified and used for the
in-vitro transcription reaction. The quality of synthesized RNA was
checked by using a Bioanalyzer with the total RNA nano kit
(Agilent Technologies).
Collection of swab samples from patients with flu
symptoms in clinical research
The clinical research was conducted according to the
Declaration of Helsinki Principles. Protocols for sample collection,
storage, and SmartAmp-based detection of 2009 pdm influenza
A(H1N1) viruses in swab samples obtained from patients were
approved by the Institutional Review Boards at Chiba Prefectural
Togane Hospital, Isumi Medical Center, and the National Center
for Global Health and Medicine. Under written informed consent,
nasopharyngeal swab samples were collected from patients with
influenza-like symptoms at each of the hospitals and associated
clinics. Transportation of those clinical samples to RIKEN was
performed according to the guidelines provided by the National
Institute of Infectious Diseases (Tokyo, Japan). Sequence analysis
of the viral genome RNA was approved by the Research Ethical
Committee at RIKEN Yokohama Institute.
Pretreatment of swab samples
Pretreatment medium contained 5% sodium dodecyl sulfate
(SDS). The swab sample from the patient was suspended in 300 ml
of pretreatment medium with a vortex mixer. A gel-filtration spin
column was prepared by swelling Sephacryl S-400 HR (GE
Healthcare, Uppsala, Sweden) with Tris-EDTA buffer (TE buffer,
pH 8.0) in a Micro Bio-Spin Chromatography Column (Bio-Lad
Laboratories, Hercules, CA, USA). Then 15 ml of suspension was
loaded onto the gel-filtration spin column, and was centrifuged at
12006 g for 1 min at room temperature. Five microliters of the
eluted solution was applied to the reaction mixture.
RT-SmartAmp assay
The RT-SmartAmp assay was performed on the reaction
mixture (25 ml of final volume) containing 1.82 mM each of FP and
TP, 0.23 mM each of OP1 and OP2, 0.68 mM BP, 0.23 mM BP-
Ex, 1.4 mM dNTPs, 20 mM Tris-HCl (pH 8.0), 30 mM potas-
sium acetate, 10 mM (NH4)2SO4, 8 mM MgSO4, 0.1% TweenH
20, 12 units of Aac DNA polymerase (K.K.DNAFORM,
Yokohama, Japan), 0.25 units of AMV reverse transcriptase
(RT) (Fermentus, Vilnius, Lithuania), into which 5 ml of the
pretreated sample was mixed. To monitor the DNA amplification
reaction proceeding at 60uC, the fluorescence of the BP-Ex primer
was observed in an Mx3000P real-time PCR machine with the
FAM filter (band pass width of 492 nm–516 nm).
Real-time qRT-PCR for analysis of viral RNA copy number
The copy number of viral RNA extracted from swab samples
was determined by quantitative RT-PCR (qRT-PCR) in a real-
time PCR system LC480 (Roche, Basel, Switzerland), where the
RealTime ready Influenza A(H1N1) Detection Set (Roche
Diagnostics GmbH, Mannheim, Germany) and the RealTime
ready RNA Virus Master (Roche Diagnostics) were used. The
standard calibration curve for qRT-PCR was obtained by stepwise
dilution of the in-vitro synthesized RNA with a known copy
number.
Analysis of viral genome sequence
Viral genome RNA (vRNA) was extracted from swab samples
with the QIAamp Viral RNA Mini Kit (QIAGEN K.K., Tokyo,
Japan) according to the manufacturer’s instructions. A multi-
segment Reverse Transcription-PCR step was then performed on
extracted vRNA by using universal influenza A primers under the
conditions previously described by Zhou et al. [42], with the
exception that we used 40 cycles, instead of 31, for the second
cycle step [6]. Amplifications by PCR of the regions of interest
were performed with Takara Ex Taq (TaKaRa BIO INC.) by
using primers flanked with the T7 promoter for the forward
primer and the SP6 promoter for the reverse primer. Two PCR
primer sets were designed for the HA segment (positions 392 to
851 with 59-taatacgactcactatagggGATTATGAGGAGCTAA-
GAGA-39 and 59-atttaggtgacactatagaaGATCCAGCATTTCT-
TTCCAT-39, and positions 792 to 1251 with 59-taatacgactcacta-
tagggACTGGACACTAGTAGAGCCG-39 and 59-atttaggtgacac-
tatagaaCTCTTTACCTACTGCTGTGA-39) and one primer set
for the NA segment (positions 417 to 976 with 59- taatacgactcac-
tatagggCCTTGGAATGCAGAACCTTC-39 and 59-atttaggtga-
cactatagaaGATTGTCTCCGAAAATCCCA-39). Samples were
then treated with ExoSAP-IT (GE Healthcare, Tokyo) and
sequenced. The resulting PCR products were subjected to direct
sequencing with a capillary 3730xl DNA Analyzer sequencer
(Applied Biosystems, Tokyo, Japan) according to the manufactur-
er’s protocol, as described previously [6].
Supporting Information
Figure S1 Time courses of the SmartAmp reaction
during detection of various copy numbers of cDNA
encoding the target sequence in the HA segment of the
2009 pdm influenza A(H1N1) virus. The reaction mixture
contained 1.82 mM each of FP and TP, 0.23 mM each of OP1 and
OP2, 0.68 mM BP, 0.23 mM BP-Ex, 1.4 mM dNTPs, 20 mM
Tris-HCl (pH 8.0), 10 mM KCl, 10 mM (NH4)2SO4,8 m M
MgSO4, 0.1% TweenH 20, 6 units of Aac DNA polymerase, and
plasmid DNA with an insert of the target sequence of the HA
segment. The copy number of the target sequence was 0, 50, 500,
or 5,000 in the reaction mixture (25 ml of volume). The SmartAmp
reaction was observed in an Mx3000P real-time PCR machine,
where the reaction temperature was maintained at 60uC and the
fluorescence of the BP-Ex primer was monitored over time.
(TIF)
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action. A: Formation of the first cDNA strand from the viral
RNA negative strand encoding the HA segment as well as the
subsequent steps of DNA polymerase reaction involved in the
SmartAmp reaction with TP, FP, OP1, and OP2 primers. B:
Creation of two DNA intermediate products derived from the
SmartAmp reaction.
(TIF)
Figure S3 Schematic illustration of sample processing
for the rapid diagnosis test using immunochromatogra-
phy kits and the SmartAmp assay-based detection of the
2009 pdm influenza A(H1N1) virus. Two swab samples were
collected from each patient to perform both the rapid influenza
diagnostic test and the RT-SmartAmp assay to detect the 2009
pdm influenza A(H1N1) virus. Those detection methods required
different pre-treatment procedures. vRNA was extracted from
those pre-treatment media and subjected to multi-segment RT-
PCR and sequence analysis, as described in Materials and
Methods.
(TIF)
Figure S4 Mutations found in the annealing sites of
SmartAmp primers in the HA segment. A total of 140
samples (RT-SmartAmp assay positive) were subjected to multi-
segment RT-PCR and sequence analysis, as described in Materials
and Methods. Red letters indicate the mutations found in the
annealing sites of the SmartAmp primers in the HA segment. The
number of samples for each mutation is given in the inset table.
(TIF)
Table S1 Cross reactivity of the SmartAmp primers to
various pathogens. The cross reactivity was tested by using
three different lots of the RT-SmartAmp primer set. ND, not
determined.
(DOC)
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